Preclinical data suggest that the effect of tasquinimod on serum PSA levels is related to its inhibitory effect on tumour growth (Dalrymple et al, 2007), which supports a hypothesis that a clinical change in PSA slope or PSADT is indicative of a therapeutic response to tasquinimod. This evidence concerns the gene KLK3 and neoplasm.